Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shenzhen Royal Asset to Pay $33 Million for Fibrosis Candidates from Prometic

publication date: Aug 14, 2017
Shenzhen Royal Asset Management (SRAM) will pay $33 million for China rights to three candidates aimed at fibrosis from Montreal's Prometic Life Sciences. SRAM will also own a 25% share in Prometic ChinaCo, a new JV that will manufacture the API for China use of the three molecules. SRAM will pay a royalty on China revenues to the JV and be responsible for China development of the in-licensed drugs, focusing initially on pulmonary and liver fibrosis. Prometic will use the $33 million for ex-China clinical trials of the three candidates. More details....

Stock Symbols: (TSX: PLI; OTCQX: PFSCF)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital